Literature DB >> 17052441

Refractory overactive bladder in men: update on novel therapies.

Casey K Ng1, Ricardo R Gonzalez, Alexis E Te.   

Abstract

Overactive bladder (OAB) in men is an entity that may be challenging to diagnose and treat, especially in the presence of bladder outlet obstruction. The application of oral medical treatments of lower urinary tract symptoms attributed to benign prostatic hyperplasia has traditionally utilized alpha-adrenergic blockers and 5alpha-reductase inhibitors. After failure of oral medical therapies, surgical options are traditionally offered. Even after surgical options are successful, lower urinary tract symptoms that are secondary to OAB persist. These patients merit a trial of antimuscarinic drugs. Additionally, certain patients with concomitant bladder outlet obstruction who have not been surgically relieved can still merit a trial of antimuscarinic drugs without significant risk of developing urinary retention. When these oral antimuscarinic drugs fail, options still remain for treating men with refractory OAB. Successful application of various diagnostic approaches and the initiation of conservative options as well as other options, such as neuromodulation for refractory urgency and urge incontinence, can help the patient. Finally, emerging data support the use of intradetrusor injections of botulinum toxin for refractory OAB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052441     DOI: 10.1007/s11934-006-0054-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  36 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.

Authors:  G Larsson; B Hallén; L Nilvebrant
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

3.  Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection.

Authors:  Christopher P Smith; Michael B Chancellor
Journal:  J Endourol       Date:  2005-09       Impact factor: 2.942

4.  Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

Authors:  M J Barry; A T Cockett; H L Holtgrewe; J D McConnell; S A Sihelnik; H N Winfield
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

5.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

6.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Steven A Kaplan; Konstantin Walmsley; Alexis E Te
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

7.  Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study.

Authors:  J J de la Rosette; W P Witjes; W Schäfer; P Abrams; J L Donovan; T J Peters; R J Millard; C Frimodt-Møller; P Kalomiris
Journal:  Neurourol Urodyn       Date:  1998       Impact factor: 2.696

8.  Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding.

Authors:  Jan Groen; J L H Ruud Bosch; Ron van Mastrigt
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

9.  Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence.

Authors:  Jerilyn M Latini; Mohammad Alipour; Karl J Kreder
Journal:  Urology       Date:  2006-03       Impact factor: 2.649

Review 10.  Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.

Authors:  Apostolos Apostolidis; Prokar Dasgupta; Clare J Fowler
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

View more
  3 in total

1.  2012 update: guidelines for adult urinary incontinence collaborative consensus document for the canadian urological association.

Authors:  Mathieu Bettez; Le Mai Tu; Kevin Carlson; Jacques Corcos; Jerzy Gajewski; Martine Jolivet; Greg Bailly
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

Review 2.  Management of OAB in those over age 65.

Authors:  Ricardo Natalin; Fabio Lorenzetti; Miriam Dambros
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 3.  Overactive Bladder Syndrome: Evaluation and Management.

Authors:  Elad Leron; Adi Y Weintraub; Salvatore A Mastrolia; Polina Schwarzman
Journal:  Curr Urol       Date:  2018-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.